Factors associated with disease-free survival in patients with FIGO stage IB1 and tumor size ≤2 cm
| Characteristics | Univariate analysis | Multivariate analysis | ||||
| HR | 95% CI | P value | Adjusted HR | 95% CI | P value | |
| Age, years | ||||||
| <50 | 1 (Ref) | – | – | 1 (Ref) | – | – |
| ≥50 | 1.035 | (0.984 to 1.089) | 0.178 | 1.600 | (0.501 to 5.112) | 0.428 |
| Histology | ||||||
| SCC | 1 (Ref) | – | – | 1 (Ref) | – | – |
| Non-SCC | 2.064 | (0.717 to 5.944) | 0.179 | 3.114 | (0.838 to 11.576) | 0.090 |
| Preoperative conization or LEEP | ||||||
| No | 1 (Ref) | – | – | 1 (Ref) | ||
| Yes | 0.382 | (0.087 to 1.682) | 0.203 | 0.211 | (0.027 to 1.659) | 0.139 |
| Grade | ||||||
| I | 1 (Ref) | – | – | 1 (Ref) | – | – |
| II–III | 0.737 | (0.202 to 2.686) | 0.644 | 1.031 | (0.262 to 4.053) | 0.965 |
| Parametrial involvement | ||||||
| No | 1 (Ref) | – | – | |||
| Yes | 0.049 | (0 to 2.231E+15) | 0.878 | |||
| Lymph node involvement | ||||||
| No | 1 (Ref) | – | – | |||
| Yes | 0.047 | (0 to 4325.232) | 0.6 | |||
| Invasion depth | ||||||
| <2/3 | 1 (Ref) | – | – | 1 (Ref) | – | – |
| ≥2/3 | 0.383 | (0.050 to 2.914) | 0.354 | 0.732 | (0.085 to 6.326) | 0.777 |
| LVSI | ||||||
| No | 1 (Ref) | – | – | 1 (Ref) | – | – |
| Yes | 0.827 | (0.188 to 3.642) | 0.802 | 2.965 | (0.546 to 16.090) | 0.208 |
| Adjuvant treatment | ||||||
| No | 1 (Ref) | – | – | 1 (Ref) | – | – |
| Yes | 0.512 | (0.146 to 1.796) | 0.296 | 0.261 | (0.048 to 1.414) | 0.119 |
| Surgical approach | ||||||
| Open surgery | 1 (Ref) | – | – | 1 (Ref) | – | – |
| Laparoscopy | 3.381 | (1.174 to 9.733) | 0.024 | 4.64 | (1.26 to 17.06) | 0.02 |
FIGO, International Federation of Gynecology and Obstetrics; LEEP, loop electrosurgical excision procedure.; LVSI, lymphovascular space invasion; Ref, reference; SCC, squamous cell carcinoma.